U.S. Markets open in 2 hrs 20 mins

Identifying Pipelines in Medical Devices: An Expert Equity Analyst Shares His Take on R&D in the Healthcare Industry and Shares Some of his Top Stock Picks

67 WALL STREET, New York - March 18, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act

Companies include: Endologix Inc. (ELGX), Thoratec Corp. (THOR), Heartware International Inc. (HTWR), Integra LifeSciences Holdings (IART), Medtronic, Inc. (MDT), MAKO Surgical Corp. (MAKO) and many more.

In the following excerpt from the Medical Devices Report, an expert analyst discusses the outlook for the sector for investors:

TWST: What kinds of things have stuck out to you during earnings this quarter?

Mr. Lichtman: So far, we've seen more of the large caps report than the small caps. One thing we've seen is some optimism in the U.S. about stability in some of these where we've seen an increasing slowdown over the last couple of years, particularly on volume and price. That's stability is certainly a good thing.

The other theme we're hearing is that Europe is slow. It's not surprising, because of a lot of the austerity measures that have been put in place. But Medtronic (MDT) in particular, when they reported earnings a few days ago, seemed to indicate that perhaps things are a little slower in January. Now, one month does not make a trend, but I think that has certainly raised some concern among investors for the whole group.

TWST: Do the small-cap names have as much concern about Europe as some of the bigger guys?

Mr. Lichtman: From a big picture, certainly. But again, the positive for the average small-cap company versus average large-cap company is less exposure to Europe at this point. Naturally, younger companies focus initially on growing products in the U.S., then expand internationally, so on average they will have less exposure to Europe today.

TWST: Any companies or segments that you're down on or concerned about right now?

Mr. Lichtman: The main concern we've had over the near term has been on the capital equipment side. One name that unfortunately had a tough year in 2012 was...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.